The FDA approved two additional treatment options for newly diagnosed older patients with AML and patients who are unable to receive intensive chemotherapy.
FDA Approves Daurismo For Some Older Patients With AML
The FDA approved oral glasdegib (Daurismo, Pfizer) for use with low-dose cytarabine (LDAC) to treat newly diagnosed acute myeloid leukemia (AML) in older adults who may not be able to receive intensive chemotherapy.